Sai Life Sciences: A Leap Forward in IPO Landscape

Sai Life Sciences, supported by TPG Capital, raised Rs 913 crore from anchor investors prior to its IPO launch. The Rs 3,043-crore IPO, opening soon, will support debt repayment and corporate purposes. The Hyderabad-based firm offers drug discovery and development services to pharmaceutical companies.

Sai Life Sciences, a prominent player backed by TPG Capital, secured Rs 913 crore from anchor investors on Tuesday, in anticipation of its initial public offering entering the market.

The anchor investors include high-profile entities such as INQ Holding LLC, Fidelity Funds, and the Abu Dhabi Investment Authority, as stated in a recent circular on the BSE platform.

With a robust portfolio, Sai Life Sciences aims to utilize IPO proceeds for debt payment and corporate goals, while it continues to serve major pharmaceutical and biotechnology firms globally.